Japan’s largest drugmaker Takeda has successfully closed a deal worth USD 62 billion to buy another pharma giant Shire grabbing a place in the top 10 pharmaceutical company list. This is the biggest pharma acquisition of this year so far. Takeda was trying to close a deal for quiet a long time and the news came on tuesday when the official announced that both the companies have made an agreement. The final valuation of Dublin based shire is set at USD 62.1 billion, excluding debt according to the officials. Including shire’s debt the buyout is worth USD 80 billion making it biggest deal ever signed by a japanese pharmaceutical company. Takeda has a market value of around USD 33 billion and the deal has left the investors in fear of how to fund the acquisition. After this deal they will enter into the western markets opening new horizons for its growth.
DelveInsight Blog
Related Article
![pharma-news-for-valneva-innovent-gsk-bayer pharma-news-for-valneva-innovent-gsk-bayer](https://assets.delveinsight.com/blog/wp-content/uploads/2024/07/23163511/pharma-news-for-valneva-innovent-gsk-bayer.png)
CEPI Grants $41.3 Million to Valneva; Innovent Achieves Phase III Success for Mazdutide; GSK’s BLENREP Combination Therapies EMA Review Application; Darolutamide Phase III ARANOTE Trial; Roche’s SUSVIMO Shows Long-Term Efficacy
CEPI Grants $41.3 Million to Valneva to Enhance Global Access to First Chikungunya Vaccine The Coalition for Epidemic Preparedness Innovations and Valneva SE have expanded their partnership to enhance access to the world's first chikungunya vaccine, IXCHIQ®, in Low- and Middle-Income Countries (LMICs). CEPI will...
Find More![pharma-news-immutep-pfizer-novo-nordisk-arcutis pharma-news-immutep-pfizer-novo-nordisk-arcutis](https://assets.delveinsight.com/blog/wp-content/uploads/2024/07/16165017/pharma-news-immutep-pfizer-novo-nordisk-arcutis.png)
Immutep’ First-Line Treatment Positive Outcomes; Pfizer’s Once-Daily Oral GLP-1 Agonist Danuglipron; FDA Issues Complete Response Letter to Novo Nordisk; Arcutis’ ZORYVE® Cream 0.15% FDA Approval; NICE Recommends Ebglyss For Moderate To Severe Atopic Dermatitis
Immutep Announces Promising Outcomes for First-Line Treatment in PD-L1 Negative Head and Neck Squamous Cell Carcinoma Patients Immutep Limited announced positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial, evaluating eftilagimod alfa (efti) combined with MSD’s anti-PD-1 therapy KEYTR...
Find More![pharma-news-for-eli-lilly-ideaya-roche-sanofi pharma-news-for-eli-lilly-ideaya-roche-sanofi](https://assets.delveinsight.com/blog/wp-content/uploads/2024/07/09162838/pharma-news-for-eli-lilly-ideaya-roche-sanofi.png)
Lilly’s Morphic Acquisition; IDEAYA’s IDE397 Positive Phase II Trial Result; XPOVIO (selinexor) Approval in China; Roche to Reintroduce Susvimo in the US; Dupixent EU Approval
Lilly Strengthens IBD Treatment Portfolio with Morphic Acquisition Eli Lilly and Company and Morphic Holding, Inc. announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for serious chronic diseases. Lilly will initiate a tender offer to acqu...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2024
![ASCO 2023 ASCO 2023](https://assets.delveinsight.com/img/events/american-society-of-clinical-oncology-conference-2024.png)
Live Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!